ストックスクリーナーアプリを入手
65.16
0.08%
-0.0645
前日終値:
$65.10
開ける：
$63.8
24時間の取引高:
396.79K
Relative Volume:
0.14
時価総額：
$9.11B
収益：
$1.09B
当期純損益:
$233.57M
株価収益率:
42.36
EPS:
1.5382
ネットキャッシュフロー:
$327.01M
1週間 パフォーマンス:
+2.62%
1か月 パフォーマンス:
+0.63%
6か月 パフォーマンス:
+123.73%
1年 パフォーマンス:
+274.92%
1日の値動き範囲:
$63.75
$65.64
1週間の範囲:
$61.26
$67.15
52週間の値動き範囲:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.08 | 9.12B | 1.09B | 233.57M | 327.01M | 1.5382 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.95 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.60 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - Yahoo Finance
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (ARWR) Competitors - Meyka
ARWR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners - simplywall.st
Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co. - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR) - Sahm
Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Net current asset value per share of Arrowhead Pharmaceuticals, Inc. – DUS:HDP1 - TradingView
Arrowhead Pharmaceuticals Achieves 201.24% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (ARWR): An Investor Outlook on Its 28.86% Potential Upside - DirectorsTalk Interviews
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
Responsive Playbooks and the ARWR Inflection - Stock Traders Daily
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp - MarketBeat
Reviewing Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Nutra Pharma (OTCMKTS:NPHC) - Defense World
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity - ChartMill
Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - Defense World
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited - Finviz
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited - Yahoo Finance
Strategic Shift in Biopharma Dealmaking - Intellectia AI
Fundamentals Check: Can Arrowhead Pharmaceuticals Inc weather a recessionEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential - DirectorsTalk Interviews
Piper Sandler highlights Arrowhead Pharmaceuticals, Inc. (ARWR) pipeline with upcoming phase III hypertriglyceridemia data - MSN
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock benefit from automationJuly 2025 Review & Weekly Chart Analysis and Trade Guides - mfd.ru
What’s the beta of Arrowhead Pharmaceuticals Inc. stockWeekly Trade Recap & Accurate Entry and Exit Point Alerts - mfd.ru
What are Arrowhead Pharmaceuticals Inc.’s recent SEC filings showingProfit Target & Capital Protection Trading Alerts - mfd.ru
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Is Arrowhead Pharmaceuticals Inc. gaining market shareTrade Risk Assessment & Verified Momentum Stock Watchlist - mfd.ru
Zacks Research Issues Negative Estimate for ARWR Earnings - MarketBeat
Johnson Investment Counsel Inc. Makes New $781,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus - Sahm
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
Arrowhead Pharmaceuticals Inc (ARWR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Jan 05 '26 |
Sale |
63.11 |
40,164 |
2,534,661 |
171,958 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 02 '26 |
Sale |
66.10 |
13,187 |
871,703 |
3,792,739 |
0.50%
大文字化:
|
ボリューム (24 時間):